Dharwad News Today

Hormone Receptor (HR) positive/ Human Epidermal Receptor 2 (HER2) negative Breast Cancer Market Insights, Epidemiology and Market Forecast 2030

 Breaking News
  • No posts were found

Hormone Receptor (HR) positive/ Human Epidermal Receptor 2 (HER2) negative Breast Cancer Market Insights, Epidemiology and Market Forecast 2030

May 08
03:55 2020
Hormone Receptor (HR) positive/ Human Epidermal Receptor 2 (HER2) negative Breast Cancer Market Insights, Epidemiology and Market Forecast 2030

Delveinsight Business Research
DelveInsight’s “HR Positive/ HER2 Negative Breast Cancer Market Insights, Epidemiology, and Market Forecast 2030” report delivers an in-depth understanding of the Hormone Receptor (HR) Positive/ Human Epidermal Receptor 2 (HER2) Negative Breast Cancer, historical and forecasted epidemiology as well as the Hormone Receptor (HR) Positive/ Human Epidermal Receptor 2 (HER2) Negative Breast Cancer market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

HR-positive/HER2-negative breast cancer is the most common form of breast cancer and also accounts for a higher percentage of all breast cancers. HR-positive cancer is usually treated with hormone therapies or a combination of hormone therapies with targeted therapy to help stop tumor growth.

A number of classes of antiestrogenic agents available for patients with early, advanced, or metastatic breast cancer includes selective estrogen receptor modulators (SERMs), aromatase inhibitors (AIs), and a selective estrogen receptor degrader.

Delveinsight’s epidemiology forecast model for HR-positive/HER2-negative Breast Cancer is based on the evaluation of all age-group female population in the 7MM countries. Attributed to the fact that there is no specific therapy for ER-positive breast cancer, and that the ER-positive therapies are targeting the entire HR-positive/HER2-negative patient population, therefore we have taken into consideration the patient pool for HR-positive/HER2-negative breast cancer patients.

Conventionally, endocrine therapies are recommended as first-line treatment management options for ER-Positive breast cancer. And, if ET do not respond well than chemotherapy is suggested by the oncologist.

 

Visit For Sample Pages: 

https://www.delveinsight.com/sample-request/hr-positive-her2-negative-breast-cancer-market-insights

 

 Hormone-Receptor-hr-positive-Human-Epidermal-Receptor-2-HER2-negative-Breast-Cancer-Market-Insights

The Hormone Receptor (HR) Positive/ Human Epidermal Receptor 2 (HER2) Negative Breast Cancer market report aslo covers emerging drugs, current treatment practices, Hormone Receptor (HR) Positive/ Human Epidermal Receptor 2 (HER2) Negative Breast Cancer market share of the individual therapies, current and forecasted Hormone Receptor (HR) Positive/ Human Epidermal Receptor 2 (HER2) Negative Breast Cancer Market Size from 2017 to 2030 segmented by seven major markets.

The report provides a detailed current Hormone Receptor (HR) Positive/ Human Epidermal Receptor 2 (HER2) Negative Breast Cancer treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market. 

 

Hormone Receptor (HR) Positive/ Human Epidermal Receptor 2 (HER2) Negative Breast Cancer Market Key Facts

  • The total incident population of breast cancer in the 7MM is expected to rise to 698,212 in 2030, during the study period [2017–2030]. 

  • Among the 7MM, the US accounts for the 80.51% USD of the overall market size of ER-positive/HER2-negative Breast Cancer in 2017.

  • In Japan, a higher number of cases were observed for postmenopausal Breast cancer, i.e., 71,280 cases post-menopause category, while only 17,820 patients were observed for premenopause in 2017.

  • The most incident cases of ER+/HER– breast cancer were recorded in the United States.

  • The lowest incident population of ER+/HER– breast cancer was recorded in Japan.

  • Among the EU5 countries, Germany accounts for the highest market size for ER-positive/HER2-negative Breast Cancer followed by France, Italy, the UK, and Spain.

 

Key Benefits of Hormone Receptor (HR) Positive/ Human Epidermal Receptor 2 (HER2) Negative Breast Cancer Market Report

  • Hormone Receptor (HR) Positive/ Human Epidermal Receptor 2 (HER2) Negative Breast Cancer market report provides an in-depth analysis of Hormone Receptor (HR) Positive/ Human Epidermal Receptor 2 (HER2) Negative Breast Cancer Market Size, Share, Trend, Epidemiology and Market Forecast till 2030, in 7 major market i.e. EU5 (Germany, Italy, Spain, France and the UK), Japan, and the United States.

  • The Hormone Receptor (HR) Positive/ Human Epidermal Receptor 2 (HER2) Negative Breast Cancer market report will help in developing business strategies by understanding the Hormone Receptor (HR) Positive/ Human Epidermal Receptor 2 (HER2) Negative Breast Cancer Market trends & developments, key players and future market competition that will shape and drive the Hormone Receptor (HR) Positive/ Human Epidermal Receptor 2 (HER2) Negative Breast Cancer market in the upcoming years.

  • The Hormone Receptor (HR) Positive/ Human Epidermal Receptor 2 (HER2) Negative Breast Cancer market report covers Hormone Receptor (HR) Positive/ Human Epidermal Receptor 2 (HER2) Negative Breast Cancer current treatment practices, emerging drugs, market share of the individual therapies in 7 MM.

  • The report provides a detailed assessment of the Hormone Receptor (HR) Positive/ Human Epidermal Receptor 2 (HER2) Negative Breast Cancer market in terms of market drivers & barriers, Unmet Needs, market opportunities, patient population,  comparative analysis of pipeline products with detailed clinical profiles, and other factors. 

 

Hormone Receptor (HR) Positive/ Human Epidermal Receptor 2 (HER2) Negative Breast Cancer Market

The Hormone Receptor (HR) Positive/ Human Epidermal Receptor 2 (HER2) Negative Breast Cancer market outlook section of the report helps to build the detailed comprehension of the historic, current and forecasted Hormone Receptor (HR) Positive/ Human Epidermal Receptor 2 (HER2) Negative Breast Cancer market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand for better technology. 

The report gives a thorough detail of Hormone Receptor (HR) Positive/ Human Epidermal Receptor 2 (HER2) Negative Breast Cancer market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, and view of the key opinion leaders. 

 

Hormone Receptor (HR) Positive/ Human Epidermal Receptor 2 (HER2) Negative Breast Cancer Epidemiology

Hormone receptors are proteins that receive hormone signals and initiate the cancer cells to grow. If breast cancer cells get signals from the hormone estrogen that could promote tumor growth, it is known as estrogen receptor-positive (ER+) breast cancer. Breast cancer that is ER-positive or PR-positive falls under the category of hormone receptor-positive (HR+) breast cancer. Breast cancer cells may have one, both, or none of these receptors.

 The Hormone Receptor (HR) Positive/ Human Epidermal Receptor 2 (HER2) Negative Breast Cancer epidemiology section covers insights about historical and current Hormone Receptor (HR) Positive/ Human Epidermal Receptor 2 (HER2) Negative Breast Cancer patient pool and forecasted trends for every seven major countries (i.e. the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030.

It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.  

 

Hormone Receptor (HR) Positive/ Human Epidermal Receptor 2 (HER2) Negative Breast Cancer Drugs Uptake and Key Market Players

The Hormone Receptor (HR) Positive/ Human Epidermal Receptor 2 (HER2) Negative Breast Cancer Drugs Uptake section focuses on the rate of uptake of the potential drugs recently launched in the Hormone Receptor (HR) Positive/ Human Epidermal Receptor 2 (HER2) Negative Breast Cancer market or expected to get launched in the market during the study period. The analysis covers Hormone Receptor (HR) Positive/ Human Epidermal Receptor 2 (HER2) Negative Breast Cancer market uptake by drugs; patient uptake by therapies; and sales of each drug.    

Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Some of the key players in Hormone Receptor (HR) Positive/ Human Epidermal Receptor 2 (HER2) Negative Breast Cancer market include

  • Pfizer

  • Novartis

  • AstraZeneca Pharmaceuticals

  • Eli Lilly

  • Novartis Pharmaceuticals

  • Pharmacia and Upjohn Company

  • Odonate Therapeutics

  • Radius Pharmaceuticals

  • Immunomedics

  • Roche

  • Syndax Pharmaceuticals

  • Takeda Pharmaceuticals

  • GlaxoSmithKline

  • Merck Sharp and Dohme Corp.

And many others.

 

Visit For Sample Pages: 

https://www.delveinsight.com/sample-request/hr-positive-her2-negative-breast-cancer-market-insights

 

Table of Content

1. Key Insights

2. Executive Summary 

3. Hormone Receptor (HR) Positive/ Human Epidermal Receptor 2 (HER2) Negative Breast Cancer Competitive Intelligence Analysis

4. Hormone Receptor (HR) Positive/ Human Epidermal Receptor 2 (HER2) Negative Breast Cancer Market Overview at a Glance

5. Hormone Receptor (HR) Positive/ Human Epidermal Receptor 2 (HER2) Negative Breast Cancer Disease Background and Overview

6. Hormone Receptor (HR) Positive/ Human Epidermal Receptor 2 (HER2) Negative Breast Cancer Patient Journey

7. Hormone Receptor (HR) Positive/ Human Epidermal Receptor 2 (HER2) Negative Breast Cancer Epidemiology and Patient Population

8. Hormone Receptor (HR) Positive/ Human Epidermal Receptor 2 (HER2) Negative Breast Cancer Treatment Algorithm, Current Treatment, and Medical Practices

9. Hormone Receptor (HR) Positive/ Human Epidermal Receptor 2 (HER2) Negative Breast Cancer Unmet Needs

10. Key Endpoints of Hormone Receptor (HR) Positive/ Human Epidermal Receptor 2 (HER2) Negative Breast Cancer Treatment

11. Hormone Receptor (HR) Positive/ Human Epidermal Receptor 2 (HER2) Negative Breast Cancer Marketed Products

12. Hormone Receptor (HR) Positive/ Human Epidermal Receptor 2 (HER2) Negative Breast Cancer Emerging Therapies

13. Hormone Receptor (HR) Positive/ Human Epidermal Receptor 2 (HER2) Negative Breast Cancer Seven Major Market Analysis

14. Attribute Analysis

15. Hormone Receptor (HR) Positive/ Human Epidermal Receptor 2 (HER2) Negative Breast Cancer Market Outlook (7 major markets)

16. Hormone Receptor (HR) Positive/ Human Epidermal Receptor 2 (HER2) Negative Breast Cancer Access and Reimbursement Overview

17. KOL Views on the Hormone Receptor (HR) Positive/ Human Epidermal Receptor 2 (HER2) Negative Breast Cancer Market.

18. Hormone Receptor (HR) Positive/ Human Epidermal Receptor 2 (HER2) Negative Breast Cancer Market Drivers

19. Hormone Receptor (HR) Positive/ Human Epidermal Receptor 2 (HER2) Negative Breast Cancer Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

 

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.

 

Related Reports-

Hormone Receptor (HR)-positive/ Human Epidermal Receptor 2 (HER2)-negative Breast Cancer Epidemiology Forecast to 2030

DelveInsight’s ‘Hormone Receptor (HR)-positive/ Human Epidermal Receptor 2 (HER2)-negative Breast Cancer – Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical and forecasted Hormone Receptor (HR)-positive/ Human Epidermal Receptor 2 (HER2)-negative Breast Cancer epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Anuj Rawat
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/

Categories